Omalizumab Antibody | AbD20669_hIgG1

//www.bio-rad-antibodies.com/omalizumab-antibody-abd20669-higg1-hca235.html
Omalizumab Antibody | AbD20669_hIgG1 gallery image 1

Human anti omalizumab specificity ELISA

A microtiter plate was coated over night with various antigens at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20669_hIgG1) at a concentration of 2 µg/ml and QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Omalizumab Antibody | AbD20669_hIgG1 gallery image 2

Human anti omalizumab specificity titration ELISA

A microtiter plate was coated over night with human IgG1/kappa, human IgG1/lambda, trastuzumab or omalizumab at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20669_hIgG1) titrated to the given concentrations in PBST+10% human serum, followed by QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Omalizumab Antibody | AbD20669_hIgG1 gallery image 3

Omalizumab bridging ELISA for Pharmacokinetic (PK) assay development

A microtiter plate was coated over night with Human anti omalizumab (clone AbD20669, HCA236) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab. Detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20669_hIgG1) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Omalizumab Antibody | AbD20669_hIgG1 gallery image 4

Human anti omalizumab bridging ELISA for Anti-Drug Antibody (ADA) assay development

A microtitre plate was coated over night with omalizumab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, PBST with (black line) or without (red line) 10% human serum was added spiked with increasing concentrations of Human anti omalizumab (clone AbD20669_hIgG1). Detection was performed using HRP-conjugated omalizumab. The addition of serum influences the binding curve of the assay due to interference from endogenous IgE

Enlarge
  • Omalizumab Antibody | AbD20669_hIgG1 thumbnail image 1
  • Omalizumab Antibody | AbD20669_hIgG1 thumbnail image 2
  • Omalizumab Antibody | AbD20669_hIgG1 thumbnail image 3
  • Omalizumab Antibody | AbD20669_hIgG1 thumbnail image 4
  • Human anti Omalizumab:HRP
  • Human anti Omalizumab
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-omalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assays for omalizumab and biosimilars. It is suitable as detection antibody in PK bridging ELISA with HCA236 to detect free drug, and as an ADA assay reference standard.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD20669_hIgG1
    • Isotype
      IgG1
    2 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA235PEdatasheet pdfdatasheet pdf0.1 mg
      HCA235P
      HCA235Edatasheet pdfdatasheet pdf0.1 mg
      HCA235
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti omalizumab, clone AbD20669_hIgG1 is a paratope specific, anti-idiotypic antibody that binds specifically to omalizumab but not to free IgE or the drug/immunoglobulin complex. The antibody can be used to measure the levels of omalizumab and biosimilar products in bioanalytical assays.

        Clone AbD20669_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with the antibody in monovalent Fab format, clone AbD20669 (HCA236), as the capture antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

        Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

        Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

        View a summary of all anti-omalizumab antibodies
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
        0.01% Thiomersal
      • Immunogen
        Omalizumab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD = 1.1 nM by real time, label free molecular interaction analysis on immobilized omalizumab.
      • Approx. Protein Concentrations
        IgG concentration 0.1 mg/ml
        IgG concentration 0.5 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
        Phosphate buffered saline
      • Storage
        Store at -70oC.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
      • Shelf Life
        12 months from date of despatch
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Xolair® is a registered trademark of Novartis.
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Xolair® is a registered trademark of Novartis.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA
      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • Recommended Protocol
      • ELISA
        This product may be used in direct ELISA and as a detection reagent in PK bridging assay together with HCA236 as the capture reagent.
        Protocol: PK bridging ELISA to measure free drug
      • ELISA
        This product may be used as bridging reagent in ADA assay development or, following HRP-conjugation, as a detection reagent in PK assay development together with HCA236 as the capture reagent.
        Protocol: PK bridging ELISA to measure free drug
        Protocol: ADA bridging ELISA
      • Immunohistology
      • Immunohistology
      • Histology Positive Control Tissue
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Immunofluorescence
      • Western Blotting
      • Western Blotting
      • Instructions For Use
      • Instructions For Use

      Additional Omalizumab Antibody Formats

      Formats Clone Applications Sizes available
      Omalizumab Antibody : Purified AbD20669_hIgG1 E 0.1 mg
      Omalizumab Antibody : HRP AbD20669_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Recombinant Human IgE LambdaHCA1710.1 mgE
            HCA171
            Recombinant Human IgE KappaHCA1900.1 mgE
            HCA190
            Human anti OmalizumabHCA2360.1 mgE
            HCA236
            Human anti Omalizumab (Drug/Target Complex)HCA2370.1 mgE
            HCA237
            Human anti Omalizumab (Drug/Target Complex)HCA2380.1 mgE
            HCA238
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A
            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            Recombinant Human IgE LambdaHCA1710.1 mgE
            HCA171
            Recombinant Human IgE KappaHCA1900.1 mgE
            HCA190
            Human anti OmalizumabHCA2360.1 mgE
            HCA236
            Human anti Omalizumab (Drug/Target Complex)HCA2370.1 mgE
            HCA237
            Human anti Omalizumab (Drug/Target Complex)HCA2380.1 mgE
            HCA238
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...

                You May Also Be Interested In...